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Background: Vaginal Escherichia coli is a reservoir along the fecal-vaginal-urinary/neonatal course of
transmission in extraintestinal E. coli infections. They also causes genital tract infections especially vaginitis,
so that detection of their antibiotic resistance is an important approach to control these infections. One
important mechanism of resistance is ESBL production by Enterobacteriaceae especially Klebsiella spp. and
Escherichia coli, which is now a worldwide problem that limits therapeutic options.
Methods: Sixty one vaginal E. coli isolates from pregnant and non-pregnant women, were detected
phenotypically and genotypically for ESBL production.
Results: Most of pregnant and non-pregnant women's isolates, were resistant to cefotaxime (100% vs. 81.5%,
respectively) and more than half of them to ceftazidime (56.5% vs. 71.0%, respectively). One hundred percent
each, 52.1% vs. 68.4%, and 73.9% vs. 60.5%%, were ESBL producers by screening, confirmatory, and PCR tests,
respectively. Pregnant women's isolates had: CTX-M- (69.5%), SHV- and OXA-type (each 4.3%) ESBLs. Only one
isolate (4.3%) had two types of ESBLs. All 16 CTX-M-positive (100%) isolates had CTX-M-1. Non-pregnant
women's isolates were predominated by SHV and CTX-M -type (44.7% vs. 39.4%, respectively), followed by
OXA- (15.7%), and TEM-type (2.6%). Of these isolates, 42.1% had two types of ESBL genes. All 15 CTX-M
-positive (100%) isolates had CTX-M-1. Pregnant and non-pregnant women's isolates differed significantly
(P≤ 0.05) regarding the expression of SHV- (4.3% vs. 44.7%, respectively) and CTX-M-type (69.5% vs. 39.4%,
respectively) ESBLs. In both, CTX-M-1 was the predominant CTX-M group (each 100%). All of the isolates were
susceptible to imipenem and meropenem, while the highest rate of resistance was against β-lactams.
Multidrug resistance was noted in 56.2% of ESBL-producing isolates.
Conclusions: Ggenital tracts of pregnant and non-pregnant women represent different environments for
propagation of ESBL-producing E. coli. In Iraq, nationwide study is required to make a precise estimation of
this widespread of ESBL-producing bacteria.
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Table 1 Nucleotide sequences of PCR primers used to
amplify four ESBL genes
Gene Primer sequence (5'-3') Amplicon
size (bp)
Reference (s)
blaTEM F AAACGCTGGTGAAAGTA 822
[11,12]
R AGCGATCTGTCTAT
blaSHV F ATGCGTTATATTCGCCTGTG 753
[11,12]
R TGCTTTGTTATTCGGGCCAA
blaCTX-M F CGCTTTGCGATGTGCAG 550
[11,12]
R ACCGCGATATCGTTGGT
blaOXA F ATATCTCTACTGTTGCATCTCC 619
[13]
R AAACCCTTCAAACCATCC
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Escherichia coli is one of the common organisms in
the vaginal microflora of pregnant as well as non-
pregnant women and it may also cause symptomatic
infections [1] such as vaginitis or tubo-ovarian abscess
and is associated with life threatening neonatal sepsis
and meningitis [2,3].
The emergence of resistance to antimicrobial agents
continues to evolve substantially, influencing the
evaluation and treatment of infections in nosocomial
and health care–associated settings and in the com-
munity. Bacteria use several strategies to avoid the effects
of antimicrobial agents, and have evolved highly efficient
means for clonal spread and for the dissemination of
resistance traits [4]. Extended-spectrum β-lactamases
(ESBLs) are capable of hydrolyzing broad spectrum cepha-
losporins and monobactams. In addition, ESBL producing
organisms exhibit co-resistance to many other classes of
antibiotics resulting in limitation of therapeutic options.
The resistant organisms are now a worldwide problem
[5-7] and their incidence is being continuously increasing
with limited treatment alternatives. It becomes necessary
to know the prevalence of these organisms and to formu-
late treatment policy [5]. Vaginal E. coli represents a real
threat specially to neonates, however, few information is
available regarding their antibiotic resistance, therefore;
this study was carried out to detect and compare, pheno-
typically and genotypically, ESBL production by E. coli iso-
lates from pregnant and non-pregnant women.
Material and methods
Patients and bacterial isolates
This study included sixty one isolates of E. coli reco-
vered as significant growth from high vaginal swabs
collected from pregnant and non-pregnant women
(aged 18–45 years) clinically diagnosed as having
symptomatic genital tract infection. The symptoms
were characterized by purulent vaginal discharge and
were recurrent despite treatment, as it was made
clear by the Gynecologists. The exact cause of infec-
tion was not further investigated in this study. These
isolates were collected over a 2-year period from May
2008 to June 2010 at Obstetrics and Gynecology Clinics in
Al-Kut City/Wasit Province/Iraq, and were identified by
conventional biochemical tests [8,9]. Performance of this re-
search was approved by the Wasit Health Administration/
Wasit Province / Iraq.
Susceptibility testing
Disk-diffusion tests were carried out with antibiotic-
containing disks (Bioanalyse) on Mueller-Hinton agar
plate (Himedia). The results were expressed as susceptible
or resistant according to the criteria recommended by the
Clinical Laboratory Standards Institute (CLSI) [10]. Thefollowing antimicrobial agents were tested: gentamicin
(CN: 10 μg), kanamicin (K: 30 μg), ciprofloxacin (CIP:
5 μg), norfloxacin (NOR: 10 μg), trimethoprim-sulfameth-
oxazole (SXT: 1.25/23.75 μg), imipenem (IMP: 10 μg),
meropenem (MEM: 10 μg), amoxicillin-clavulanic acid
(AMC: 20/10 μg), cefotaxime (CTX: 30 μg), ceftazidime
(CAZ: 30 μg ), ceftriaxone (CRO: 30 μg ), and aztreonam
(ATM: 30 μg).Phenotypic screening for ESBL
Screening of reduced susceptibility to third generation
cephalosporins was carried out using Cefotaxime
(CTX) and ceftazidime (CAZ) discs and double-disk
synergy (DDS) method was used to confirm the pres-
ence of ESBLs as recommended by the Clinical and
Laboratory Standards Institute [10].PCR amplification for detection of β-lactamase genes
All isolates were screened for the resistance genes TEM,
SHV, CTX-M, and OXA by a multiplex PCR assay using
universal primers (Table 1) [11-13]. Each isolate was
subcultured on trypticase soy agar plates for 24 h at 37°
C. From the agar plate, 5 colonies were picked and
suspended in 100 μl sterile distilled water. Bacterial
suspensions were run for 10 min at 94°C [14] in a DNA
thermocycler (MultiGene, Labnet International, Inc.,
USA) and cell debris were removed by centrifugation
(12,000 rpm for 1 min). PCR amplification reactions
were performed in a volume of 50 μl containing 25 μl of
KapaTaq 2x Ready Mix (KAPA Biosystems, USA), 25
pmol concentrations of each primer, and 5 μl of DNA
template. The cycling parameters were as follows: an ini-
tial denaturation at 94°C for 5 min; followed by 35 cycles
of 94°C for 30 s, 45°C for 1 min, and 72°C for 1 min;
and with a final extension at 72°C for 10 min. The amp-
lified PCR products were subjected to electrophoresis at
a 2% agarose gel in 0.5X TBE buffer.
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CTX-M-positive isolates were further analyzed for
CTX-M phylogroups (CTX-M-1; -2; -8; -9 and −25/
26) by multiplex PCR [15]. Primer pairs and predicted
amplicon sizes were summarized in Table 2. Amplifi-
cation conditions were: initial denaturation at 94°C
for 5 min; 30 cycles of 94°C for 25 s; 52°C for 40 s
and 72°C for 50 s; and a final extension at 72°C for







blaCTX-M-1 F AAA AAT CAC TGC GCC AGT TC 415
R AGC TTA TTC ATC GCC ACG TT
blaCTX-M-2 F CGA CGC TAC CCC TGC TAT T 552
R CCA GCG TCA GAT TTT TCA GG
blaCTX-M-8 F TCG CGT TAA GCG GAT GAT GC 666
[15]
R CAA AGA GAG TGC AAC GGA TG
blaCTX-M-9 F CAA AGA GAG TGC AAC GGA TG 205
R ATT GGA AAG CGT TCA TCA CC
blaCTX-M-25/-26 F GCA CGA TGA CAT TCG GG 327
R AAC CCA CGA TGT GGG TAG CStatistical analysis
The Chi Square test was used for statistical comparison of
groups; values < 0.05 were regarded as significant [16].Table 3 Resistance pattern of vaginal E. coli isolates to antiba
Antibacterial agent*
Pregnant women's isolates N













% Multidrug resistance 36.8 50.0
* For all the tested antibiotics (tested later in the study), the total number of isolate
instability), except for cefotaxime and ceftazidime (tested early during the study) thResults
All of the vaginal E. coli isolates included in this study
were susceptible to imipenem and meropenem, whereas
all of them were resistant to amoxicillin-clavulanic acid.
For both pregnant and non-pregnant women's isolates
the highest rate of resistance was against β-lactams
(Table 3), while resistance to other antibiotic's classes was
moderate. Multidrug resistance was noted among 45.0%
of all the isolates (36.8% and 50.0% of pregnant and non-
pregnant women's isolates, respectively) and 56.2% of
ESBL-producing isolates (50.0% and 61.1% of pregnant
and non-pregnant women's isolates, respectively).
ESBL production by these isolates also was detected
and compared by phenotypic and genotypic procedures
(Table 4).
All pregnant women's isolates (100%) were resistant to
CTX and more than half of them (56.5%) were resistant to
CAZ. All isolates (100%) were suspected producers of
ESBLs and 52.1% were confirmed phenotypically to be
ESBL producers. ESBL genotypes were detected in 73.9%
(17/23) of these isolates. CTX-M-type ESBL was the most
common (69.5%) followed by SHV- and OXA-types (each
4.3%). None of these isolates had TEM-type ESBL. Only
one isolate (4.3%) had two types of ESBLs (CTX-M- and
SHV-type) and it was resistant to both CTX and CAZ. All
CTX-M-positive (100%) isolates had only CTX-M-1.
For non-pregnant women's isolates, phenotypically,
81.5% and 71.0% were resistant to CTX and CAZ,
respectively. All of them (100%) were suspected producers
of ESBLs, whereas 26 (68.4%) were ESBL producers by
confirmatory test (Table 3). ESBL genotypes were detectedcterial agents
% of Resistant isolates
on-pregnant women's isolates All isolates
otal (n = 32) ESBL+ (n = 18) Total (n = 51) ESBL+ (n = 32)
18.75 27.7 25.4 37.5
43.7 50.0 37.2 43.7
28.1 38.8 29.4 40.6
21.8 27.7 (21.5 31.2
53.1 72.2 45.0 59.3
0 0 0 0
0 0 0 0
100 100 100 100
78.1 91.3 86.2 93.7
71.8 78.2 66.6 81.2
46.8 61.1 45.0 59.3
46.8 61.1 45.0 59.3
50.0 61.1 45.0 56.2
s was 51 (10 isolates were lost during storage as a result of electricity
e number of isolates was 61.
Table 4 Numbers (percentages) of ESBL producing vaginal E. coli isolates from pregnant and non-pregnant women







Resistance to: CTX 23 (100): R:19; I:4 31 (81.5): R = 27; I = 4 54 (88.5)
CAZ 13 (56.5): R: 11; I: 2 27 (71.0): R = 26; I = 1 40 (65.5)
Phenotypic detection of ESBLs: Screening test 23 (100) 38 (100) 61 (100)
Confirmatory test (DDST) 12 (52.1) 26 (68.4) 38 (62.2)
Genotypic detection of ESBLs (bla genotype): CTX-M 16 (69.5) 15 (39.4%) 31 (50.8)
SHV 1 (4.3) 17 (44.7) 18 (29.5)
TEM 0 1 (2.6) 1 (1.6)
OXA 1 (4.3) 6 (15.7) 7 (11.4)
ESBLs: extended spectrum β-lactamases; CTX: cefotaxime; CAZ: ceftazidime; R: resistant; I: intermediate resistant; DDST: double disc synergy test.
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found with predominance of SHV- and CTX-M-type
(44.7% vs. 39.4, respectively), followed by OXA- (15.7%),
and TEM-type (2.6%). Of these isolates, 16/38 (42.1%) had
two types of ESBL genes: ten (10/16: 62.5%) were SHV-
and CTX-M-positive; five (5/16: 31.2%) were OXA- and
CTX-M-positive and one (1/16: 6.2%) was OXA- and
SHV-type positive. All isolates with two types of ESBLs
were resistant to both CTX and CAZ except one isolate
with genotype of SHV- and OXA-type, which had inter-
mediate resistance to CTX and was sensitive to CAZ.
CTX-M-1 was expressed by all CTX-M-positive isolates.
Pregnant and non-pregnant women's isolates differed
significantly (P≤ 0.05) regarding the expression of SHV-
(4.3% vs. 44.7%, respectively) and CTX-M-type (69.5%
vs. 39.4%, respectively) ESBLs (Figure 1). One (2.6%) of
non-pregnant women's isolates had TEM-type ESBL,

























Figure 1 Comparison of ESBL genotypes' distribution among vaginalDiscussion
This study was designed to detect and compare ESBLs'
distribution among vaginal E. coli isolates from pregnant
and non-pregnant women. Most of this study-included
isolates were resistant to CTX and more than half of them
were resistant to CAZ. All of CAZ resistant isolates were
also resistant to CTX. The members of Enterobacteriaceae
possess many mechanisms of resistance to β-lactam anti-
biotics, however, β-lactamases are the most common and
clinically significant mechanism of resistance to β-lactam
antibiotics among this bacterial group [7]. Four types of
ESBLs were detected in this study, namely: TEM-, SHV-,
CTX-M-, and OXA-type. Of this study-included isolates,
65.5% (40/61) were ESBL producers by PCR technique. In
Iraq, previous researchers [17,18] reported ESBL produc-
tion by 100% of enteropathogenic E. coli (EPEC) isolates
from infants, most of them were suffering from watery
diarrhea for more than 10 days, for that they were hospi-




E. coli isolates from pregnant and non-pregnant women.
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patients and it is well known that the main source of ESBL
producers was nosocomial and also even recent hospital
contact may lead to colonization with these ESBL
producers [4,19]. In addition, the prevalence of ESBLs
differs among patient groups and clinical and geographic
settings [20]. This high ESBL frequency reported in this
study and in previous studies [17,18] is due mainly to the
lack of control over prescription and sales of antibiotics
here in Iraq, together with a lack of attention to laboratory
screening of ESBL production by clinical isolates. Only at
the level of academic research at the Universities, this
subject is recently under study. In comparison with neigh-
boring countries, this high percent of ESBL production
noted in this study, is in agreement with what is found in
Iran where 56% [21] of E. coli isolates were ESBL pro-
ducers, and in Turkey where 74.6% [22] of E. coli isolates
from hospitalized patients, and 36.7% of isolates from out-
patients [23] were ESBL producers. While it is higher than
that noted in Arab Gulf countries, such as Saudi Arabia
[24] and Kuwait [25] (10% and 26% of hospital isolates,
respectively, and 4% and 12% of community isolates,
respectively). These geographical differences in the rates
of ESBL production from country to country and even
within countries from hospital-to-hospital, were reviewed
by others [19,20].
The most common ESBL type found in this study
was CTX-M, followed by SHV and OXA types, while
TEM-type was rare. This result is consistent with the
present situation in most parts of the world, where
CTX-M-type have replaced TEM and SHV types
[26] and became the predominant ESBL among
Enterobacteriaceae in most parts of the world inclu-
ding the Middle East area, where they are prevalent
not only in nosocomial environment, but also in the
community setting [19,20,27]. The high distribution of
CTX-M-type ESBLs (50.8%) and CTX-M-1 (50.8%)
among this study's isolates explains the high rate of resist-
ance to CTX (88.5%) in comparison to CAZ (65.5%), since
CTX-M β-lactamases, in contrast to most TEM and
SHV ESBLs, preferentially hydrolyze cefotaxime over
ceftazidime [28,29] but their hydrolyzing activity have in-
creased to involve CAZ as a result of point mutations
around the active site of some enzymes belonging to the
CTX-M-1 and CTX-M-9 groups [30].
High proportion (42.1%) of non-pregnant women's
isolates had two types of ESBL genotypes versus only
4.3% of pregnant women's isolates. It seems likely that
both genital and intestinal tracts of pregnant and non-
pregnant women represent different colonization envi-
ronments for E. coli in terms of types of antibiotics
that can be used for treatment of each. During preg-
nancy there is a limitation of types of antibiotics that
should be used in order not to affect the fetus.Therefore, there is differences in selective pressure
that selects for emergence of resistance [31].
The risk of this widespread of ESBL-producing E. coli
strains resides not only in rendering oxyimino-cephalo-
sporins ineffective, but also these organisms pose a thera-
peutic challenge, since they are frequently resistant to
other kinds of antimicrobial drugs, including aminogly-
cosides, quinolones, and cotrimoxazole [4,20]. The plas-
mids bearing the genes encoding ESBLs frequently also
carry genes encoding resistance to aminoglycosides and
trimethioprim/sulfamethoxazole. There have been increa-
sing reports of plasmid-encoded decrease in susceptibility
to quinolones, frequently in association with plasmid-
mediated cephalosporin resistance. Even when plasmid-
encoded decrease in quinolone susceptibility is not
present, there is a strong association between quinolone
resistance and ESBL production [19]. In this study, 59.2%
(50.0% and 61.1% of pregnant and non-pregnant women's
isolates, respectively) of ESBL-producing isolates were
multidrug resistant (Table 3), showing resistance to genta-
micin and kanamicin (37.5% and 43.7%, respectively),
ciprofloxcin and norfloxacin (40.6% and 31.2%, respect-
ively), and trimethoprim-sulfamethoxazole (59.3%). In
Iraq, aminoglycosides, quinolones and trimethoprim-
sulfamethoxazole are widely and heavily used for treat-
ment of different infections, in addition to different types
of β-lactams, more than third-generation cephalosporins.
This high dependence on these drugs may be responsible
for the emergence of ESBL-producing strains rather than
the extensive use of third-generation cephalosporins for
treatment. Paterson and Bonomo [19] reviewed that the
use of a variety of other antibiotic classes (quinolones,
trimethoprim-sulfamethoxazole, aminoglycosides, and
metronidazole) has been found to be associated with
subsequent infections due to ESBL-producing organisms.
Conversely, prior use of β-lactam/β-lactamase inhibitor
combinations, penicillins, or carbapenems seems not to be
associated with frequent infections with ESBL-producing
organisms.
Vaginal colonization by ESBL-producing E. coli provides
a reservoir for future infections both in these women and
their contacts. The women themselves are vulnerable to
acute and recurrent urinary tract infections with vaginal
strains [32] as well as there is the possibility of transferring
such strains to their sexual partners [33]. The nosocomial
risk of vaginal colonization by such isolates resides in the
possibility of creation of an outbreak in the hospital envi-
ronment especially in the neonatal intensive care unit
(NICU) as a result of the transfer of these isolates from
the mother to the neonate during delivery. In Switzerland
[34], an outbreak of ESBL-producing E. coli in a neonatal
intermediate care unit was reported. Initial transmission
was from a mother to her newborn twins and subse-
quently by physical contact of health care workers with
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Similar results were reported from Iran, where Feizabadi
et al. [35] carried out a genetic analysis of ESBL-
producing Klebsiella pneumoniae nosocomial isolates and
found that the clonal spread played a role in the dissemi-
nation of ESBL-producing isolates in the NICU, as a result
of relatedness of a multi-drug resistant K. pneumoniae
clone detected in the NICU to a clone isolated from
women's surgery, since both of them produced similar
pulsed-field gel electrophoresis (PFGE) patterns.
In conclusion, genital tracts of pregnant and non-
pregnant women represent different environments for
propagation of ESBL-producing E. coli. In Iraq, nationwide
study is required to make a precise estimation of this
widespread of ESBL-producing bacteria.
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